BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38328795)

  • 1. Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma.
    Fitzsimmons CM; Mandler MD; Lunger JC; Chan D; Maligireddy SS; Schmiechen AC; Gamage ST; Link C; Jenkins LM; Chan K; Andresson T; Crooks DR; Meier JL; Linehan WM; Batista PJ
    NAR Cancer; 2024 Mar; 6(1):zcae004. PubMed ID: 38328795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite.
    Perez M; Bak DW; Bergholtz SE; Crooks DR; Arimilli BS; Yang Y; Weerapana E; Linehan WM; Meier JL
    J Biol Chem; 2020 Sep; 295(39):13410-13418. PubMed ID: 32820045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
    Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
    Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In deep bioinformatic characterization of a novel fumarate hydratase variant FH c.199T > G; (p.Tyr67Asp) in hereditary leiomyomatosis and renal cell carcinoma.
    Chami A; de Souza Zózimo TR; Alves TM; Matosinho CGR; Santos C; Simões MM; Cabral WLR; de Paula Ricardo BF; da Silva Filho AL; Carvalho MRS; da Conceição Braga L
    Fam Cancer; 2023 Oct; 22(4):481-486. PubMed ID: 37316640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
    Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
    Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell Cancer.
    Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
    Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer.
    Pithukpakorn M; Wei MH; Toure O; Steinbach PJ; Glenn GM; Zbar B; Linehan WM; Toro JR
    J Med Genet; 2006 Sep; 43(9):755-62. PubMed ID: 16597677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fumarate hydratase as a therapeutic target in renal cancer.
    Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
    Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary leiomyomatosis and renal cell carcinoma.
    Schmidt LS; Linehan WM
    Int J Nephrol Renovasc Dis; 2014; 7():253-60. PubMed ID: 25018647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
    Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
    BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
    Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
    Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.
    Toro JR; Nickerson ML; Wei MH; Warren MB; Glenn GM; Turner ML; Stewart L; Duray P; Tourre O; Sharma N; Choyke P; Stratton P; Merino M; Walther MM; Linehan WM; Schmidt LS; Zbar B
    Am J Hum Genet; 2003 Jul; 73(1):95-106. PubMed ID: 12772087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
    Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
    J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata.
    Shi Y; Xu Y; Wang C; Chen Y; Ren X; Kang Y; Wang C
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A CASE OF FUMARATE HYDRATASE (FH)-DEFICIENT RENAL CELL CARCINOMA SUSPECTED OF HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA].
    Hagiwara K; Urakami S; Sakaguchi K; Nagamoto S; Hayashida M; Oka S; Ogawa K; Okaneya T; Fujii T; Nagashima Y; Furuya M
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(3):141-145. PubMed ID: 35858809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].
    Rupp N; Moch H
    Pathologe; 2021 Nov; 42(6):560-564. PubMed ID: 34448900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
    Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare insights into cancer biology.
    Adam J; Yang M; Soga T; Pollard PJ
    Oncogene; 2014 May; 33(20):2547-56. PubMed ID: 23812428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
    Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
    Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).
    Chan E; Rabban JT; Mak J; Zaloudek C; Garg K
    Am J Surg Pathol; 2019 Sep; 43(9):1170-1179. PubMed ID: 31162287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.